


Omigapil maleate

Cat. No.:	HY-16361A
CAS No.:	200189-97-5
Molecular Formula:	C ₂₃ H ₂₁ NO ₅
Molecular Weight:	391.42
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (127.74 mM; ultrasonic and warming and heat to 80°C)																							
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent Concentration</th> <th colspan="3">Mass</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>Preparing Stock Solutions</td> <td></td> <td></td> <td></td> </tr> <tr> <td>1 mM</td> <td>2.5548 mL</td> <td>12.7740 mL</td> <td>25.5480 mL</td> </tr> <tr> <td>5 mM</td> <td>0.5110 mL</td> <td>2.5548 mL</td> <td>5.1096 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2555 mL</td> <td>1.2774 mL</td> <td>2.5548 mL</td> </tr> </tbody> </table>	Solvent Concentration	Mass			1 mg	5 mg	10 mg	Preparing Stock Solutions				1 mM	2.5548 mL	12.7740 mL	25.5480 mL	5 mM	0.5110 mL	2.5548 mL	5.1096 mL	10 mM	0.2555 mL	1.2774 mL	2.5548 mL
Solvent Concentration	Mass																							
	1 mg	5 mg	10 mg																					
Preparing Stock Solutions																								
1 mM	2.5548 mL	12.7740 mL	25.5480 mL																					
5 mM	0.5110 mL	2.5548 mL	5.1096 mL																					
10 mM	0.2555 mL	1.2774 mL	2.5548 mL																					
	Please refer to the solubility information to select the appropriate solvent.																							
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution 																							

BIOLOGICAL ACTIVITY

Description	Omigapil maleate, an orally bioavailable GAPDH nitrosylation inhibitor, abrogates Aβ ₁₋₄₂ -induced tau acetylation, memory impairment, and locomotor dysfunction in mice. Omigapil maleate has the potential for the research of Alzheimer's disease [1]. Omigapil maleate (CGP3446B maleate) is a apoptosis inhibitor. Omigapil maleate can be used for the research of congenital muscular dystrophy (CMD)[2]. Omigapil (maleate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.
IC₅₀ & Target	Apoptosis ^[2]
In Vivo	Treatment of mice with Omigapil (0.1 mg/kg) results in improved muscle regeneration and increased force ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	12-week-old dyW/ mag mice ^[2]
Dosage:	0.1 mg/kg
Administration:	For the first week of drug treatment, administered once daily by intraperitoneal injection. After weaning (3 weeks of age), applied once daily by oral gavage.
Result:	Reduced the muscle fibre loss. Many of the functional parameters were significantly improved by omigapil.

REFERENCES

- [1]. Sarina Meinen, et al. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. *EMBO Mol Med*. 2011 Aug;3(8):465-79.
- [2]. Tanusree Sen, et al. Nitrosylation of GAPDH augments pathological tau acetylation upon exposure to amyloid- β . *Sci Signal*. 2018 Mar 20;11(522):eaao6765.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA